Press Releases

Date Title and Summary Additional Formats
Toggle Summary Seattle Genetics Announces More Than 30 Presentations at ASH 2018 Highlighting Progress with Broad ADCETRIS® (Brentuximab Vedotin) Development Program
-Positive Phase 3 ECHELON-2 Clinical Trial Results to be Presented in Oral Session on Monday, December 3 rd - BOTHELL, Wash. --(BUSINESS WIRE)--Nov. 1, 2018-- Seattle Genetics, Inc. (Nasdaq:SGEN) today announced that 31 abstracts featuring data from the broad ADCETRIS (brentuximab vedotin)
View HTML
Toggle Summary Seattle Genetics Announces Multiple Data Presentations Evaluating ADCETRIS® (Brentuximab Vedotin) in Patients with Hodgkin Lymphoma at ISHL 2018
-Encore and Additional Analyses from Phase 3 ECHELON-1 Trial Evaluating ADCETRIS in Combination with Chemotherapy in Frontline Advanced HL- -Interim Results from Ongoing Studies of ADCETRIS plus Opdivo ® (Nivolumab) in Frontline or Relapsed Hodgkin Lymphoma- -Five-Year Results from Phase 3 AETHERA
View HTML
Toggle Summary Seattle Genetics Reports Third Quarter 2018 Financial Results
-ADCETRIS ® (Brentuximab Vedotin) Net Sales in U.S. and Canada of $127.0 Million in the Third Quarter- -Positive Top-line Data from ADCETRIS Phase 3 ECHELON-2 Trial in Frontline PTCL; Supplemental BLA Planned for November 2018 ; Full Data to be Presented at ASH Annual Meeting- -Top-line Data from
View HTML
Toggle Summary Genmab and Seattle Genetics Announce Tisotumab Vedotin Data to Be Presented at ESMO 2018 Congress
Data presented from updated analysis of full innovaTV 201 expansion cohort in recurrent or metastatic cervical cancer COPENHAGEN, Denmark & BOTHELL, Wash. --(BUSINESS WIRE)--Oct. 8, 2018-- Genmab A/S (Nasdaq Copenhagen: GEN) and Seattle Genetics, Inc.
View HTML
Toggle Summary Seattle Genetics to Host Conference Call and Webcast Discussion of Third Quarter Financial Results on October 25, 2018
BOTHELL, Wash. --(BUSINESS WIRE)--Oct. 3, 2018-- Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that it will report its third quarter financial results on Thursday, October 25, 2018 after the close of financial markets. Following the announcement, company management will host a conference
View HTML
Toggle Summary Seattle Genetics and Takeda Announce Positive Results from Phase 3 ECHELON-2 Clinical Trial Evaluating ADCETRIS® (Brentuximab Vedotin) in Frontline CD30-Expressing Peripheral T-Cell Lymphoma
-ADCETRIS in Combination with Chemotherapy Achieved Primary Endpoint, Demonstrating a Statistically Significant Improvement in Progression-Free Survival Compared to a Standard of Care Chemotherapy- -Statistically Significant Improvement Achieved in All Key Secondary Endpoints, Including Overall
View HTML
Toggle Summary Seattle Genetics Announces ADCETRIS® (Brentuximab Vedotin) Approval in Japan for Frontline Hodgkin Lymphoma
-Approval Triggers Milestone Payment to Seattle Genetics of $10 Million - BOTHELL, Wash. --(BUSINESS WIRE)--Sep. 21, 2018-- Seattle Genetics, Inc. (Nasdaq: SGEN) today announced that its collaborator, Takeda Pharmaceutical Company Limited (Takeda), has received approval from the Japanese Ministry
View HTML
Toggle Summary Seattle Genetics to Present at the Morgan Stanley Global Healthcare Conference
BOTHELL, Wash. --(BUSINESS WIRE)--Sep. 4, 2018-- Seattle Genetics, Inc. (NASDAQ:SGEN) announced today that management will present at the Morgan Stanley Global Healthcare Conference on Thursday, September 13, 2018 at 2:05 p.m. EDT . The presentation will be webcast live and available for replay
View HTML
Toggle Summary Seattle Genetics Reports Second Quarter 2018 Financial Results
-Record ADCETRIS ®  (Brentuximab Vedotin) Net Sales in U.S. and Canada of $122.4 Million in the Second Quarter- -ADCETRIS ECHELON-2 Top-line Results Expected in Early Fourth Quarter 2018- -Enrollment Completed in Pivotal Trial Cohort of Enfortumab Vedotin in Metastatic Urothelial Cancer; EV
View HTML
Toggle Summary Seattle Genetics Announces First Patient Dosed in Phase 2 innovaTV 207 Trial Evaluating Tisotumab Vedotin in Multiple Solid Tumors
-Trial to Inform Broader Development Program Strategy- -Trial is Enrolling Patients with Colorectal, Non-Small Cell Lung, Pancreatic or Head and Neck Cancers- BOTHELL, Wash. --(BUSINESS WIRE)--Jul. 12, 2018-- Seattle Genetics, Inc. (Nasdaq:SGEN) today announced dosing of the first patient in the
View HTML